



ELF

EUROPEAN
LUNG
FOUNDATION



ANNUAL REPORT

EUROPEAN LUNG FOUNDATION



It feels like no time at all since I met many of you during our time at the ERS Congress in Milan when I started my 3-year mandate as ELF Chair. I had the pleasure of working with and learning from Kjeld Hansen, past-ELF Chair, and I was excited for him to pass on the torch and for me to build on his innovation and achievements.

I believe patients can change the world, just by being themselves. I know already from our activities this year, we are learning from each other and inspiring others to take action. I observed this at Patient Organisation Networking Day in Milan, with over 500 people attending online or in-person from more than 80 countries! And this continued with our ELF patient conferences where we strengthen the collaboration between patients and experts to showcase the latest information and research.

We know it is not just patients that can make change. I have met many fellow patients, professionals, advocates and passionate volunteers all working towards the same goal. Because we all have lungs! We all have it in us to change and empower others. With ELF, we can give people the information, the action and the opportunity. With ELF, we can all make a difference.

I want to share my mandate with you to better the lives of patients. We all have different skills, needs and conditions, but we ALL need to be at the centre of change. Together, we can co-design healthcare solutions and empower whole communities. Not just patients, everyone.

In this review, I am happy to share exciting updates from Team ELF and highlight the ways we continue to meet our goals. I hope you can celebrate with me the incredible achievements, driven by our patients and stakeholders.

Let us keep the vision of the European Lung Foundation alive through collaboration and our shared passion. And for those who were there and remember my words at the ERS Congress, remember “in this life journey every breath counts” and the journey together continues...

A handwritten signature in purple ink, enclosed within a large, loopy oval. The signature appears to be 'K. Hansen'.

STRATEGY UPDATE 2023-2026

BE PATIENT DRIVEN ELF will ensure that patients and patient organisations drive its activities and that they are at the heart of all that it does. <u>Page 4</u>	IMPROVE KNOWLEDGE AND UNDERSTANDING ELF will further develop its health and science communication and provide accurate and evidence-based information for patients and the public in new formats. <u>Page 8</u>	ENGAGE AND EMPOWER ELF will continue to lead in patient engagement and involvement to improve diagnostics, treatment and care in all lung conditions and promote self-management. <u>Page 10</u>	HAVE A STRONG AND DIVERSE COMMUNITY AND VOICE ELF will participate in and help build advocacy projects to advance the lung health agenda. <u>Page 12</u>	ENSURE GOOD GOVERNANCE To deliver on the ELF strategy, the governance of ELF must be effective and efficient for employees and collaborators. <u>Page 17</u>	INCREASE RESOURCE AND REACH ELF must continue to diversify its income to ensure it can deliver on its aim to reach more people. <u>Page 18</u>
---	--	---	---	---	---

You can read a full overview of the [ELF Strategy Report on our website.](#)

1. BE PATIENT DRIVEN



ELF continues to be led by patients and patient organisations. All our work and activities are made possible through our close collaboration with people with lung conditions, patient organisations, healthcare professionals and the public.

"The power of the patient voice is ever growing in ELF! Patient participation and involvement is vital for many new treatment pathways. How can we not feel inspired by people coming together, giving their free time in the hope that they see better lung health for all? Our patient advisory groups are inspiring and transformative and bring alive real patient concerns, which are heard and understood. This is an exciting time to be involved in ELF."

Helen Parks, ELF Council



We believe that those most impacted by poor lung health are best placed to design and input into all our activities. This is why we work closely with patients and find new opportunities for them to share their experiences and opinions within healthcare.

18

**patient advisory
groups (PAGs)**

5

**cross-disease
working groups**

3

**EU project-specific
patient groups**

16

**new lived
experience videos**

Our patient advisory groups and working groups are made up of people who have an interest in a particular lung condition or topic related to lung health. Volunteers share their views and experiences and get involved in projects to help improve treatment and healthcare. This drives our activities throughout the year, including patient conferences, educational resource updates and collaborations with respiratory partners and organisations.



- The **ELF Pulmonary Hypertension PAG** was established this year, with plans to host their first event in May 2024.
- The **ELF Sarcoidosis PAG** focused on increasing awareness of their activities. The members recruited new patient associations from France and Croatia, designed a new PAG page on the ELF website and worked with ERN-Lung to establish the ERN-Lung Sarcoidosis Core Network.
- The **Pulmonary Fibrosis (PF) PAG** in collaboration with EU-PFF, carried out a survey of PF patients to understand the issues around accessing oxygen therapy across Europe. The aim was to highlight disparities and advocate for change.
- ELF held the first **Breathe Clean Air patient conference** to explore the science behind the impact of air pollution and climate change on people with lung conditions. Experts shared proven ways to mitigate the impact, and advocate for better policy around clean air. A new working group was established to continue this work.

BREATHE CLEAN AIR CONFERENCE, 7 DECEMBER 2023

150 attendees
170 views of the recording
(last updated 01/04/2024)

- This year, ELF introduced new working groups which bring together patients and professionals on key cross-disease topics. These include climate change and air pollution, digital health, youth, mental health and transplantation.
- On Saturday 23 March, 2024, we hosted the **fourth annual Bronchiectasis Patient Conference**, with live talks and videos from both bronchiectasis patients and medical experts. 797 people attended the conference from 82 countries.

“Every session was very informative even for those of us who have attended each year with good personal experience.”

“As professionals we can learn a lot from the patients’ experiences.”



BRONCHIECTASIS PATIENT CONFERENCE, 23 MARCH 2024

797 attendees (82 countries)
1,149 views of the recording
(last updated 01/04/2024)



46

projects in collaboration with ERS projects

(including 23 tasks forces and 23 clinical research collaborations (CRCs))

Patient involvement in ERS activities and publications accelerates each year* with a range of publications, lay guidelines and patient-facing materials produced as a result.

In 2023, the ERS launched the 'Guidelines in Focus' video interview series. Each new episode accompanies the release of an ERS or collaborative clinical guideline, statement or technical standard. Many of the interviews also include a patient perspective:

- Guidelines in Focus: Palliative care for people with COPD or ILD
- Guidelines in Focus: the use of ICS Formoterol in mild asthma
- Guidelines in Focus: ERS/EBMT clinical practice guideline on treatment of pulmonary chronic graft-versus-host disease in adults



Available on the ERS Respiratory channel

- The ELF team and past-chair Kjeld Hansen took part in the ERS course Virtual school on patient and public involvement in research: Working in partnership. Over 200 professionals registered for the event with 67% rating the programme quality excellent and 30% as good.
- ELF Bronchiectasis PAG members were involved in reviewing patient documentation for two EMBARC clinical trial studies: the GREAT-2 study and BRIDGE study. The purpose of the studies being to test new treatment and to improve personalised medicine for people with bronchiectasis.
- The SHARP project continued to partner with our four main stakeholder groups: patients, clinicians, researchers, and pharmaceutical partners, to achieve their mission to create a strong pan-European community of severe asthma experts. The new patient co-chair Hilary Hodge joined in February 2024 and is focusing on improving communication and highlighting to patients the important work of SHARP.

"Our perspectives were often considered and respected and we were treated as equal partners."

Phil Collis, patient representative

*(2012=1, 2015=10, 2020=30, 2021=35, 2022=39, 2023=40)

Ed Powell is 17 years old and was diagnosed with non-cystic fibrosis bronchiectasis at the age of 8 after first showing symptoms at 5 months old. He has been involved with the Child-BEAR-Net clinical research collaboration and this year he joined the ELF Council and is supporting the development of a new ELF Youth Group.



“ Growing up has not been an easy journey for me or my parents. The different diagnoses and not knowing what was wrong with me created difficulties and uncertainty. Fortunately, today I have a diagnosis and my symptoms seen to be under control - but I do not take this for granted. When I was diagnosed with bronchiectasis there was little information available about my condition in children. This led my parents to do their own research and in 2019 my mother joined an ERS task force for childhood and adolescent bronchiectasis. In 2022, I started working alongside her and have seen first-hand the value of patients contributing to guidelines and information.

Patient involvement in medical research is really important. Patients can provide a unique perspective on conditions, as living with a condition day-to-day is often different to what the professionals see in clinical practice. Patient involvement can also ensure the outcomes of projects are relevant and important to patients. While it can be daunting working alongside leading specialists in your condition, the professionals I work with really value my input and experiences. Patient voices are not just important for research. It is also important to show that people living with a lung condition are not alone, something that ELF are passionate about.

We all have the opportunity to empower patients and support change and research into lung conditions. Through ELF, patients can interact with each other and healthcare professionals and can share helpful tips which have aided them to get through difficult times. This happens through patient advisory group meetings and taskforces, as well as events like the annual ELF Bronchiectasis Patient Conference, which I was invited to speak at this year.

Looking to the future, I am excited about introduction of the new ELF Youth Group. I had the opportunity to speak about my own experiences and the importance of lung health in young people at the European Parliament in March 2024. It was great to be able to talk about problems that young people face around drug doses and quality of life. I was happy to know that youth voices were really being heard on the international stage - but we can do more. The ELF youth group can prioritise patient issues with a focus on young people. I hope we can create a safe space for young people to explore and develop ideas for advocacy and campaigning and address the problems that many young people face with lung health. ”

2. IMPROVE KNOWLEDGE AND UNDERSTANDING



ELF has increased the number of evidence-based resources available to patients and the public in multiple languages. We ensure that accurate and reliable information is available to those who need it and that they continue to be informed on lung health issues and related developments.

8

new and updated information pages

- [Pulmonary hypertension](#)
- [Transition from child to adult care](#)
- [Lung Transplant](#)
- [Antimicrobial resistance \(AMR\)](#)
- [Breathlessness \(Better-B\)](#)
- [E-cigarettes, heated tobacco and smokeless tobacco products](#) (from new ERS position paper)
- [Pulmonary fibrosis: a supportive guide](#)
- [Bronchiectasis](#) information update

3

lay guidelines and resources

- Lay guideline: [Treating Graft-vs-host disease](#)
- [News article on ERS statement on frailty in adults with chronic lung disease](#)
- New webpage on [palliative care](#) based on ERS guideline

17

lay news articles

**32,294 total news
item views (2023/24)**

- Large study sheds light on bronchiectasis in Europe (**501 views**)
- Bronchiectasis self-care guide launched this World Bronchiectasis Day (**458 views**)
- Conversation with Filipe Paixão (**381 views**)

Read more publications here:
www.europeanlung.org/en/publications

10

contributions to ERS publications

- [COPD in the 21st Century](#) (ERM)
- [The Transition of Respiratory Care: from Child to Adult](#) (ERM)*
- [COVID-19: An update](#) (ERM)*
- [ERS guideline: Palliative care for people with COPD or interstitial lung disease](#)
- [ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma](#)
- [ERS statement on management of incidental findings from low dose CT screening for lung cancer](#)
- [ERS statement on airway clearance techniques in adults with bronchiectasis](#)
- [ERS statement on frailty in adults with chronic lung disease](#)
- [ERS statement on dyspnoea in acutely ill mechanically ventilated adult patients](#)
- [ERS guideline on treatment of pulmonary chronic graft-versus-host disease in adults](#)

*To be published after April 2024

Register: elearning.epaonline.eu



The European Patient Ambassador Programme (EPAP) is a free, online, self-learning programme that introduces patients and carers to some of the basic skills and knowledge needed to represent themselves and others successfully.

Training modules include:

- Being better informed
- Improving awareness
- Improving treatment and care
- Supporting research and development
- Influencing policy
- Working with the media
- Participating in healthcare conferences
- International health research projects



EPAP
European Patient Ambassador Programme

In 2024, EPAP was translated into Ukrainian with the support of Pulmonary Hypertension Ukrainian Rare Disease Association (PHURDA). This development was designed to make EPAP accessible to people in Ukraine and Ukrainian speakers around the world. We would like to thank PHURDA for their support in creating our Ukrainian version and their continued support in helping us to reach people who could benefit from the programme in Ukraine.


EPAP is now available in 8 languages: Dutch, English, French, German, Italian, Spanish, Portuguese and Ukrainian.

117
new learners,
with 286 complete
modules

“The European Patient Ambassador Programme (EPAP) continues to expand its impact by providing patients in Europe with the tools to actively protect their rights and participate in healthcare processes. The availability of EPAP in Ukrainian is crucial as it gives Ukrainian patients the opportunity to engage in the European healthcare dialogue, ensuring their voice at the international level.”

ELF Council member, Oksana Kulish Skaara

3. ENGAGE AND EMPOWER



ELF strives to find new ways to engage different audiences and connect with people across the globe. Our online channels are key to this strategic area and ensure we can continue to lead in patient engagement and involvement through:

- recruitment for our patient communities and involvement in EU projects
- publishing evidence-based and trusted information on lung health, prevention and advocacy activities
- sharing news of ongoing work and activities from organisations within the ELF patient network
- promoting engagement and interaction between patients, professionals and the public through important discussions on lung health

909K

website users

1.3M

webpage views

11.5K

newsletter subscribers

26.2K

social media followers

Supported by content from our patient advisory groups and partners, ELF has accelerated our social media approach with more visual content and an increased number of posts published each week to help us reach out to new audiences and those who will benefit from resources in our information hub.



7,942 FOLLOWERS
Post impressions 315,490
Post engagement 4.64%



14,011 FOLLOWERS
Post impressions 357,106
Post engagement 2.84%



2,313 FOLLOWERS
Post impressions 75,187
Post engagement 7.09%



2,009 FOLLOWERS
Post impressions 73,734
Post engagement 5.74%



This year the newsletter was split into two monthly roundups: the ELF Newsletter and our new ‘Patient Voice’ mailing. The aim of Patient Voice is to give more visibility to our patient-centred content, spotlight articles and Patient Organisation Round-up. We also began sending more direct single-message mailings about events and opportunities to those that opted in.

Audience summary:



	MARCH 2023	MARCH 2024
ELF Newsletter	11280	11,520
Patient Voice mailing	/	11,387

As part of the new approach to mailings, we are asking for more information about our audience by surveying current subscribers and adding more questions on the newsletter subscription form. This has helped us get to know our audience better and we can then tailor relevant content to them.

Email performance:



	2022/2023	2023/2024
Emails sent	121,813	172,754
Average open rate	36.2%	36.4%
Average click rate	2.8%	3.2%

Subscribe to the ELF Newsletter here:
www.europeanlung.org/en/news/newsletters

4. HAVE A STRONG AND DIVERSE COMMUNITY AND VOICE



ELF participates in and helps to build advocacy projects which can advance the lung health agenda. There have been a number of opportunities to work with patients to amplify their voices and experiences, including patient speakers at the ERS Congress, involvement in EU projects and events in Brussels.

We continued to work in partnership with ERS to bring patients and the public together with healthcare professionals to improve lung health and advance diagnosis, treatment and care. This work was accelerated through Lungs Europe, the MEP Lung Health Group and the European Lung Health Group.

Highlights

- The ERS, the International Society for Environmental Epidemiology (ISEE) and the Health Effects Institute (HEI) hosted the **Clean Air in Europe for All** conference that was focused on air pollution, in May 2023. Among the participants was ELF Chair, Kjeld Hansen, who talked about the need to empower the voices of patients and to better understand the link between air pollution and health.
- In September 2023, the European Parliament agreed to support the full alignment of the new EU air quality standards with those of the World Health Organization (WHO), but with a five-year delay. In October, ELF and ERS published a **joint statement** to warn about the significant consequences such a delay could cause.
- The European Lung Health Group (ELHG) presented a new pan-European initiative to raise awareness about lung health at the European Respiratory Society International Congress 2023.
- In January, ELF joined the ERS event **Endgame begins now** to discuss issues around the UK's proposed tobacco cessation policy, which aims to stop the sale of tobacco to individuals born from 2009 onwards.
- February 2024 marked the launch of the new ELHG publication: **"#KeepBreathing: A vision for EU action on lung health 2024-2029"**. The document lays out an immediate action plan to improve lung health across three areas – prevention, care and research – for a healthier, stronger and more resilient society in Europe.



"[The patient's talk] was heartfelt, compelling, and really centred the discussions at the symposium. People like her are why we do what we do."

"I found the 2 patient videos excellent and also very educational. Having the patients 'present' in our sessions makes the whole effort more meaningful."

"In my current job I sometimes feel a bit isolated from the rehabilitation community. [The patient's] testimony has reminded me why we are doing what we do and inspired me to try harder to maximise the benefits of exercise for people with chronic lung disease. Thank you!"

"[The patient's] talk was excellent and really framed the work to follow with most (all?) speakers using her powerful contribution as a reference point for their presentations. She also gave the closing comments in the Q&A which were crucial."



**INTERNATIONAL
CONGRESS 2023**
MILAN Italy, 9-13 September

Patients at ERS Congress, Milan 2023

Due to the COVID-19 pandemic, the Congress was held virtually in 2020 and 2021. In 2022, it was held in a hybrid format with reduced in-person capacity. This year, the ERS Congress returned to normal capacity and there was an opportunity for patient organisations to participate in person in Milan or access the Congress online. ELF is committed to ensuring patient organisations and patient representatives have the opportunity to attend the ERS Congress and contribute their valuable expertise to the programme.

14

**patients and carers
were invited to be a
part of ERS Congress
sessions**

12

**videos produced
for ERS Congress**

8

**patients recorded
in a language
other than English**

115

registrations
from organisations and
patient representatives to
access ERS Congress
programme

Patient organisation networking day

ELF Patient organisation networking day is an annual event during the [ERS Congress](#) that brings together organisations in the ELF Patient organisation network to learn about and discuss important topics in lung health. The 2023 event took place on Saturday 9 September and focussed on patient and public involvement in research and mental health. We offered a hybrid event for 2023, with the chance to attend in person in Milan or join online.

82

attended in Milan

488

attended online

80

**countries
represented**

85%

**rated the event as
good or excellent**



Our involvement with EU projects and international committees is vital to ensure that patients' voices are at the centre of change. By working on EU projects we can ensure that patients are at the very heart of state-of-the-art research and policy changes. We have been proud to be part of:

DRAGON concluded in March 2024 after three years. The project used artificial intelligence (AI) and machine learning to deliver a decision support system for precise coronavirus diagnosis using CT scanning. It also aimed to be able to better predict the outcomes of patients.

The logo for the DRAGON project, featuring the word "DRAGON" in a blue sans-serif font with a blue gear icon replacing the letter "O".

ELF's work in the project involved empowering patients to be more involved in their coronavirus diagnosis, care and preparedness. A patient and public advisory group was created to advise and input throughout the course of the project. This year, the ELF team and patient representatives attended and spoke at the final DRAGON conference in Brussels in June 2023. We also produced new resources on [data sharing in healthcare](#) and [remote care: looking after your health using digital tools](#).

After the success of the DRAGON project, the ERS CONNECT clinical research collaboration (CRC) has been established to continue work on the theme of digital healthcare.

The **BETTER-B** project also concluded this year. The project investigated attitudes to breathlessness amongst health professionals and trialled a new medicine for people who are severely affected by breathlessness. ELF worked with the project to update our existing resource on managing breathlessness. A new clinical practice review is being prepared on the management of breathlessness. It will be published and translated on the ELF website next year.

The logo for the BETTER-B project, featuring the text "BETTER-B" in a blue sans-serif font with a blue swoosh underline.

The EU-funded **FAIR** project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome AMR in pneumonia. ELF is involved in communication and dissemination together with the ERS. In the last year, ELF supported the promotion of a new survey which asked patients to share their views about a new treatment for lung infections.

The logo for the FAIR project, featuring a stylized green and blue flagellin molecule icon next to the text "FAIR" in a blue sans-serif font, with "FLAGELLIN AEROSOL THERAPY" in smaller text below.



3TR is the largest IMI project yet, focussing on autoimmune, inflammatory and allergic diseases including COPD and asthma. The project aims to provide insights into mechanisms of response and non-response to treatment across different diseases. ELF joined patient representatives from 7 diseases areas in Stockholm for the 3TR annual meeting. The event included a patient panel which discussed the values and challenges of the project from patient perspective.




OPTIMA is an Innovative Medicines Initiative (IMI)-funded EU project aiming to ensure that every patient with lung, prostate and breast cancer has access to the most up-to-date individualised treatments and innovative therapies. It will do this by strengthening shared decision-making using dynamic computer-interpretable guidelines and using AI-driven technology and tools.

The OPTIMA Public and Patient Advisory Board (PPAB) have taken part in various activities this year including regular work package meetings and reviewing surveys and materials. In May 2023, PPAB members attended the OPTIMA AGM in Barcelona and gave a presentation on their activities to date.



UNITE4TB is a 7-year project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active TB treatment regimens for drug-resistant and -sensitive TB. The UNITE4TB Community Advisory Group (CAG) have been very active in the last year with regular meetings with representatives from one of the UNITE4TB clinical trials, and supporting the review of protocols, PPI plans and recruitment materials. The CAG have attended a number of events including the UNITE4TB AGM in Nijmegen in April 2023, the UN Multi-stakeholder Hearing on TB in May 2023 and the UNION World Conference in November 2023.



Learn more about our EU Projects:
www.europeanlung.org/en/projects-and-campaigns/eu-projects



This year, we honoured Stefano Boeri, an Italian architect, urban planner and academic, with the 2023 ELF Award for his inspirational work to improve air quality in urban environments. The award recognises individuals, groups or organisations who have made an outstanding contribution to the service of human health in the respiratory field.

Stefano Boeri's designs integrate living nature into the urban environment: several international studies have shown that living and working closely connected with trees and plants can lead to reduced stress levels and improved physical and mental health, as well as improved air quality with consequent positive impact on lung health.

Kjeld Hansen, ELF Chair at the time of the award, commended the work of Stefano Boeri: "We are delighted to honour Stefano Boeri with our annual award. His work represents an innovative and sustainable approach to architecture and urban planning. By taking innovative strides in the field and inspiring other architects, his work that has the potential to benefit the environment and health and well-being of generations to come."



50+
press articles
published about the
ELF Award 2023

"I am happy and proud of this important award. Green offers extraordinary benefits, it helps to mitigate urban heat – making cities more livable – and to absorb CO2 and fine particles, making cities and our lungs healthier; for this reason, for over 20 years, we have been working to develop ideas and projects aimed at multiplying trees and forests in urban areas. Our "Green Obsession" is a planning commitment and at the same time an aspiration that we would like to share with anyone who looks with courage and optimism at the future of our cities and the quality of life of all citizens."

Stefano Boeri, Italian architect and academic (pictured left)

5. ENSURE GOOD GOVERNANCE



In September 2023, we welcomed Dimitris Kontopidis as the new ELF Chair. Dimitris has years of experience in patient advocacy, working with the cystic fibrosis (CF) community and changing the face of CF care in Greece and across Europe.

ELF knows that to truly represent the voice of patients that it must be driven by patients and Dimitris advocacy work for innovation and research in CF provided the team with confidence and excitement for his mandate.

"If we want to see what the challenges of our times are, I think that digital transformations are changing the way we will interact with health services. Nowadays, the hospital is not in the hospital, it is transferred to the office, at home in our pocket, with various mobile devices. Real world data – our data, can help us make timely predictions and targeted prevention. Technology can reduce inequalities. Now the patient behaves more like a user with different expectations and characteristics. We want the solutions to be designed for each patient, so they must be at the centre of the design of each service and patient-centred policies. Thus, the strategy of the next 3 years will be based on 3 values:

- **PATIENT DRIVEN** policy decisions and co-design services with patient experts
- **EMPOWERING COMMUNITIES** of patients, doctors and stakeholders.
- **MULTI-KNOWLEDGE NETWORKS** exchange know-how and promote partnerships, adopting good practices."

"I would like to invite each of you, whether you are patients with various respiratory diseases or people from different countries and professional backgrounds, to take an active part in the journey of the 3 next years, let's plan together our future days for unlimited breath. Because you know best, that in our life's journey, every breath counts."

6. INCREASE RESOURCE AND REACH

ELF recognises the need to diversify its income to ensure we can continue to deliver on our objectives and reach out to more people and patients.

- This year, ELF grew its annual fundraised income to **€104,888**. It is clear that ELF continues to work and deliver in areas of common interest to funders and donors. We hope to continue to grow and strengthen this.
- Through the development of strategic partnerships, ELF can maximise the impact of this funding through activities such as Healthy Lungs for Life and the global grants programme.
- We held our **Annual Stakeholder Meeting** in October 2023 to discuss our achievements from the last year and give stakeholders an opportunity to feed into our strategic activities and priorities for the next financial year. It was also a fantastic opportunity to recognise the contribution of our volunteers and supporters and give them the chance to feed into future funding priorities and activities.

Thank you to our key partners who have supported 'Healthy Lungs for Life' and ELF activities this year:

CLEAN
AIR
FUND





The Healthy Lungs for Life campaign is run by ELF and ERS. It focusses on five key themes to raise awareness on the best ways we can keep our lungs healthy and reduce the amount lung disease experienced by people worldwide.



Healthy Lungs for Life, Milan 2023

The campaign visited Milan as part of the ERS Congress in September 2023. ELF worked in partnership with Forestami to offer free lung tests at the Piazza XXV Aprile and a chance to learn more about clean air and keeping lungs healthy.

500 people attended the event in Piazza XXV Aprile	500+ people signed a petition to show their support for clean air policies	262 total press articles published about the event
--	---	--

“Today, the great challenge for Milan is to improve the quality of the air we breathe in the city, to improve the health and lives of its citizens: a recent survey commissioned by C40 shows that this is an issue that worries the Milanese.

“The campaign carried out by ERS and ELF aims to explain the social, health and also economic impact of the damage caused by bad air and how this can be prevented...”

Giuseppe Sala, Mayor of the Municipality
of Milan and Vice-President of C4

Community grants



Thanks to the support of the Forum of International Respiratory Societies (FIRS) and Clean Air Fund, ELF was able to offer 18 grants to organisations around the globe to promote the Healthy Lungs for Life campaign.

The events and activities reached tens of thousands of people in countries including:

- Cameroon
- Nigeria (2 projects)
- Mexico
- Kenya
- Brazil (2 projects)
- Nepal
- Greece & Cyprus (one project)
- Spain
- France
- Ghana
- Pakistan
- Serbia
- Slovenia
- Greece
- Italy
- Turkey



FINANCIAL REVIEW 2023/24



*In 2023/24, the income from ERS was reduced. This was due to ELF using funds from our reserves.

SUPPORT OUR WORK

USE YOUR VOICE AND EXPERIENCE

Patient voices matter. We are always introducing more opportunities for patients to contribute to our work. Get involved in our disease-specific patient advisory groups (PAGs) or new cross-disease working groups.

If you want to use your experiences to help others, to inform healthcare professionals and to shape policy decisions then please consider joining Team ELF!

GET INVOLVED

VOLUNTEER YOUR TIME, SKILLS AND KNOWLEDGE

There are many ways to support our work, from helping to offer spirometry tests at ERS Congress and our Healthy Lungs for Life events, to translating our lay texts into multiple languages.

Volunteering your time and skills helps us to keep costs down and focus our resources on trying to engage new audiences, launch new campaigns and take part in more projects.

GET IN TOUCH

DONATE!

ELF continues to ensure patients are at the heart of our work.

Please help us to continue this work and become a regular donor today. Your donations help us to plan for our future and ensure that lung health patients continue to have their voices heard on a European and global level.

DONATE TODAY



EUROPEAN LUNG FOUNDATION

ELF is a patient-led organisation that works internationally to bring patients and the public together with healthcare professionals to improve lung health and advance diagnosis, treatment and care.

Founded in 2000, ELF works in partnership with the European Respiratory Society (ERS) to develop the union between lung health professionals and patients. Based in Sheffield (UK) and Brussels (Belgium) ELF has grown and developed a core team of specialists and a network of individual patients and patient organisations. Our ethos is openness, inclusiveness and collaboration. We believe in working together to improve lung health.

UK Address

442 Glossop Road
Sheffield
S10 2PX
UK

Website

www.europeanlung.org

EU Address

51 Rue de Treves
Brussels
1040
BE

Email

info@europeanlung.org

Charity number: 1118930

